[Remission induction treatment in adults with acute myeloid leukemia. 8-year experience with 2 successive protocols]

Med Clin (Barc). 1989 Apr 29;92(16):601-4.
[Article in Spanish]

Abstract

We report our eight year experience remission induction therapy in adult patients with acute myeloblastic leukemia. Overall 67 patients were treated, with a mean age of 43.3 years (range 15-75). Two treatment protocols were used. Complete remission (CR) was achieved in 23 patients of 39 receiving protocol A (58%). The 28 last patients were treated with the more aggressive protocol B, and CR was achieved in 23 patients (82%). CR was achieved in 68% of the overall group. The most outstanding predictive factors were age above 30 years, and M-5 morphology as indicating a poor prognosis.

Publication types

  • Comparative Study
  • English Abstract

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cytarabine / administration & dosage
  • Doxorubicin / administration & dosage
  • Female
  • Humans
  • Leukemia, Erythroblastic, Acute / drug therapy
  • Leukemia, Monocytic, Acute / drug therapy
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / pathology
  • Leukemia, Myelomonocytic, Acute / drug therapy
  • Leukemia, Promyelocytic, Acute / drug therapy
  • Male
  • Middle Aged
  • Prednisolone / administration & dosage
  • Prognosis
  • Remission Induction*
  • Vincristine / administration & dosage

Substances

  • Cytarabine
  • Vincristine
  • Doxorubicin
  • Prednisolone